VIRUSGA QARSHI PREPARATLAR BILAN DAVOLASHNING O‘ZIGA XOS XUSUSIYATLARI
DOI:
https://doi.org/10.5281/zenodo.18312128Keywords:
Virusga qarshi preparatlar, antiviral terapiya, virus replikatsiyasi, farmakokinetika, farmakodinamika, resistentlik, yon ta’sirlar, individualizatsiyalashgan davolash, immun modulatsiya, profilaktika, vaksinalar, klinik qo‘llanilish, virusli infeksiyalar, yangi avlod dori vositalari, global standartlarAbstract
Virusga qarshi preparatlar bilan davolash zamonaviy tibbiyotda infeksion kasalliklarning oldini olish va ularni samarali davolashning muhim yo‘nalishlaridan biri hisoblanadi. Ushbu maqolada virusga qarshi dori vositalarining farmakologik xususiyatlari, ta’sir mexanizmlari va klinik qo‘llanilish sohalari tahlil qilinadi. Viruslarga qarshi preparatlar ikki asosiy guruhga bo‘linadi: retseptor blokatorlari va virusning replikatsiya jarayonini to‘xtatuvchi agentlar. Ularning samaradorligi virus turi, bemorning klinik holati, immun statusi va qo‘llash vaqtiga bog‘liq. Shuningdek, preparatlarning metabolizm va farmakokinetik xususiyatlari, yon ta’sirlari, dori-dori o‘zaro ta’sirlari va resistentlik shakllanishi kabi omillar ham klinik amaliyotda e’tiborga olinadi. Virusga qarshi terapiya individualizatsiyalangan bo‘lishi, davolash rejimi va dozalash bemorning yoshi, og‘irligi, boshqa surunkali kasalliklari hamda homiladorlik holati kabi parametrlar asosida tanlanadi.
References
De Clercq, E. The history of antiviral agents and their discovery. Antiviral Research, 2019;168:104–123. Elsevier.
Hayden, F.G., Shindo, N. Influenza virus infections: antiviral therapy and management. Infectious Disease Clinics of North America, 2019;33(4):141–159. Elsevier.
Crotty, S., Cameron, C.E., Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proceedings of the National Academy of Sciences, 2000;97(12):6895–6900. National Academy of Sciences.
De Clercq, E. Antiviral drug discovery: ten more compounds, and ten more stories. Med Res Rev, 2004;24(6):667–700. Wiley.
Pizzorno, A., Padey, B., Terrier, O., Rosa-Calatrava, M. Antiviral strategies against influenza virus: focus on neuraminidase inhibitors. Frontiers in Microbiology, 2019;10:276. Frontiers Media.
Richman, D.D., et al. Antiviral drug resistance. New England Journal of Medicine, 2016;374:836–847. Massachusetts Medical Society.
De Clercq, E. Strategies in antiviral drug design. Nature Reviews Drug Discovery, 2013;12:111–129. Springer Nature.
Whitley, R.J., Gnann, J.W. Antiviral therapy of herpesvirus infections. Journal of Infectious Diseases, 2002;186(Suppl 1):S23–S34. Oxford University Press.
Lalezari, J.P. Current concepts in antiviral therapy. Clinical Infectious Diseases, 2001;32:141–151. Oxford University Press.
Smee, D.F., et al. Development of new antiviral agents. Antiviral Chemistry & Chemotherapy, 2001;12:1–15. International Medical Press.
Морозов, С.В. Современная антивирусная терапия: основы и практические рекомендации. Москва: Медицина, 2017;256 с.
Иванова, Е.А. Фармакологические аспекты применения противовирусных препаратов. Санкт-Петербург: Питер, 2018;312 с.
Abdusamatova, D.A., Askarova, Z.Z. Virusga qarshi preparatlar bilan davolash: klinik va farmakologik aspektlar. Samarqand: SDMU Nashriyoti, 2022;120 s.
Karimov, T., Saidov, A. Infektsion kasalliklarda antiviral terapiya strategiyalari. Toshkent: TDTU Nashriyoti, 2021;142 s.
Fauci, A.S., Lane, H.C., Redfield, R.R. Covid-19 — Navigating the uncharted. New England Journal of Medicine, 2020;382:1268–1269. Massachusetts Medical Society.
Gandhi, R.T., et al. Antiviral therapy for HIV infection. JAMA, 2018;320(4):347–358. American Medical Association.
Taylor, R., et al. Emerging antiviral agents and therapeutic strategies. The Lancet, 2020;395:2293–2305. Elsevier.
World Health Organization (WHO). Guidelines for the clinical management of viral infections. Geneva: WHO Press, 2021;84 s
